Patient demographics, clinical characteristics and prior treatments
| Patients (N=135) | |
| Age (mean±SD) | 69.1 (10.5) |
| Male | 59 (43.7) |
| Smoking status | |
| Never | 82 (60.7) |
| Ex-smoker | 23 (17.0) |
| Current | 30 (22.2) |
| Comorbidities | |
| Cardiovascular disease | 32 (23.7) |
| Diabetes mellitus | 13 (9.6) |
| Stroke | 12 (8.9) |
| Treatment | |
| Inhaled bronchodilators | 88 (65.2) |
| Inhaled corticosteroids | 59 (43.7) |
| Inhaled antibiotics | 6 (4.4) |
| Chronic macrolide therapy | 31 (23.0) |
| FEV1 (% predicted) (mean±SD) | 78.3 (28.3) |
| FVC (% predicted) (mean±SD) | 94.3 (27.0) |
| BMI (kg/m2) (mean±SD) | 25.9 (5.6) |
| Aetiology | |
| Idiopathic | 61 (45.2) |
| Postinfective | 22 (16.3) |
| Post-tuberculosis | 12 (8.9) |
| COPD | 12 (8.9) |
| Rheumatoid arthritis | 6 (4.4) |
| CTD | 4 (3.0) |
| ABPA | 4 (3.0) |
| Primary ciliary dyskinesia | 3 (2.2) |
| Inflammatory bowel disease | 3 (2.2) |
| Asthma | 3 (2.2) |
| Haematological malignancy-associated immunodeficiency | 2 (1.5) |
| Young syndrome | 2 (1.5) |
| Specific antibody deficiency | 1 (0.7) |
| Exacerbations in previous 12 months | |
| 0 | 24 (17.8) |
| 1 | 28 (20.7) |
| 2 | 15 (11.1) |
| 3 | 20 (14.8) |
| ≥4 | 48 (35.6) |
| BSI (mean±SD) | 8.0 (4.3) |
| FACED (mean±SD) | 2.4 (1.5) |
Data are expressed by n (%) as otherwise is indicated
ABPA, allergic bronchopulmonary aspergillosis ; BMI, body mass index; BSI, Bronchiectasis Severity Index; COPD, chronic obstructive pulmonary disease; CTD, connective tissue disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.